Infanrix Hexa Vaccine is a combined immunization designed to protect infants and young children against six serious infectious diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis, and Haemophilus influenzae type b (Hib). This vaccine contains diphtheria toxoid (30 IU), tetanus toxoid (40 IU), pertussis toxoid (25 mcg), filamentous haemagglutinin (25 mcg), pertactin (8 mcg), recombinant hepatitis B surface antigen (10 mcg), inactivated poliovirus types 1, 2, and 3 (40D, 8D, and 32D antigen units respectively), and Hib capsular polysaccharide (10 mcg). Administered intramuscularly, Infanrix Hexa stimulates the immune system to produce protective antibodies against these pathogens, thereby reducing the risk of infection and associated complications. It is typically given as part of routine childhood immunization schedules, with doses administered at specified intervals to ensure optimal immunity. The vaccine’s safety and efficacy have been established through extensive clinical trials. Common side effects are generally mild and transient, including localized pain, redness, or swelling at the injection site, and occasionally mild fever or irritability. Infanrix Hexa is contraindicated in individuals with known hypersensitivity to any component of the vaccine or a history of severe allergic reaction following a previous dose. It is essential to follow national immunization guidelines and consult healthcare professionals for appropriate use.